Tempest Therapeutics, Inc.
TPSTNext catalyst
IO-108
Advanced Liver Cancers
Get an email about TPST's next catalysts
Track Tempest Therapeutics (TPST) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 1 past
IO-108 Phase 2 Est. Readout (MORPHEUS-LIVER)
Estimated primary completion for IO-108 trial (NCT04524871) in Advanced Liver Cancers. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
No drugs found in this phase.
Frequently asked questions
When is Tempest Therapeutics, Inc.'s next FDA catalyst?→
Tempest Therapeutics, Inc.'s (TPST) next tracked catalyst is a Phase 2 readout expected Q3 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track TPST biotech catalysts?→
Add TPST to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Tempest Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.